Symbol not found

NASDAQ:TRVN   00:00AM GMT
0.00
0.00 (0.00%)
Earnings Announcements

Trevena Reports Positive Topline Olinvyk Cognitive Function Data

Published: 07/28/2022 11:37 GMT
Trevena Inc (TRVN) - Trevena Announces Positive Topline Olinvyk Cognitive Function Data and Provides General Business Update.
Trevena Inc - Olinvyk Demonstrated Statistically Significant Reduced Impact on Neurocognitive Functioning Versus Iv Morphine on Primary Endpoint.
Trevena Inc - Novel S1p Receptor Modulator Trv045 for Diabetic Neuropathic Pain on Track for Completion of Phase 1 in 2h 2022.
Trevena Inc - Strategic Allocation of Resources and Cost Reductions Reinforce Key Focus Areas and Extends Cash Runway to Mid-2023.
Revenue is expected to be $0.46 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $1.67 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.